Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy

Int J Clin Pharmacol Ther. 2022 Aug;60(8):370-372. doi: 10.5414/CP204243.
No abstract available

MeSH terms

  • Carcinoma, Ovarian Epithelial / drug therapy
  • Female
  • Humans
  • Indazoles
  • Indoles
  • Ovarian Neoplasms* / drug therapy
  • Phthalazines
  • Piperazines
  • Piperidines
  • Platinum / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors* / adverse effects

Substances

  • Indazoles
  • Indoles
  • Phthalazines
  • Piperazines
  • Piperidines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Platinum
  • rucaparib
  • niraparib
  • olaparib